The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Comparative Risk of Serious Infections With Biologic and/or Immunosuppressive Therapy in Patients With Inflammatory Bowel Diseases: A Systematic Review and Meta-Analysis
Open accessAbstract
Background and Aims: We performed a systematic review and meta-analysis to evaluate the comparative risk of serious infections with tumor necrosis factor-α (TNFα) antagonists, biologic agents that do not inhibit TNFα, tofacitinib, and immunosuppressive agents in inflammatory bowel diseases (IBD). Methods: Through a systematic search until March 18, 2018, we included 15 observational studies (>500 person-years) in patients with IBD treated with TNFi, non-TNFi biologics, tofacitinib and/or IS monotherapy (thiopurines, methotrexate), reporting the risk of serious infections. Studies reporting active comparators were included, to allow appropriate comparative synthesis. We performed random effects meta-analysis and estimated relative risk (RR) and 95% CIs. Results: Compared to monotherapy with a TNFα antagonist, risk of serious infection increased with the combination of a TNFα antagonist and an immunosuppressive agent (in 6 cohorts; RR, 1.19; 95% CI, 1.03–1.37), with a TNFα antagonist and corticosteroids (in 4 cohorts; RR, 1.64; 95% CI, 1.33–2.03), or with all 3 drugs (in 2 cohorts; RR, 1.35; 95% CI, 1.04–1.77); there was minimal heterogeneity among studies. In contrast, monotherapy with an immunosuppressive agent was associated with a lower risk of serious infections than monotherapy with a TNFα antagonist (7 cohorts; RR, 0.61; 95% CI, 0.44–0.84) or a TNFα antagonist with an immunosuppressive agent (2 cohorts; RR, 0.56; 95% CI, 0.39–0.81). Infliximab-based therapy was associated with lower risk of serious infections as compared to adalimumab-based therapy in patients with ulcerative colitis (4 cohorts; RR, 0.57 [0.33–0.97]), but not Crohn’s disease (4 cohorts; RR, 0.91 [0.49–1.70]). Few data are available on the comparative safety of biologic agents that do not inhibit TNFα and tofacitinib. Conclusion: Combination therapies for IBD that include TNFα antagonists, especially with corticosteroids, are associated with higher risk of serious infection, whereas monotherapy with an immunosuppressive agent is associated with lower risk, compared to monotherapy with a TNFα antagonist. Studies are needed to evaluate the comparative safety of biologic agents that do not inhibit TNFα and tofacitinib for treatment of IBD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Assessing Bias in Studies of Prognostic Factors
Hayden, J. A., van der Windt, D. A., Cartwright, J. L., Côté, P., & Bombardier, C. (2013) · Annals of Internal Medicine · doi:10.7326/0003-4819-158-4-201302190-00009 · Cited by 3,287
How to read a funnel plot in a meta-analysis
Sedgwick, P., & Marston, L. (2015) · BMJ · doi:10.1136/bmj.h4718 · Cited by 318
Cited by
The Medical Management of Paediatric Crohn’s Disease: an ECCO-ESPGHAN Guideline Update
van Rheenen, P. F., Aloi, M., Assa, A., Bronsky, J., Escher, J. C., Fagerberg, U. L., Gasparetto, M., Gerasimidis, K., Griffiths, A., Henderson, P., et al. (2021) · Journal of Crohn's and Colitis · doi:10.1093/ecco-jcc/jjaa161 · Cited by 729
Dolinger, M., Torres, J., & Vermeire, S. (2024) · The Lancet · doi:10.1016/s0140-6736(23)02586-2 · Cited by 580
Kucharzik, T., Ellul, P., Greuter, T., Rahier, J. F., Verstockt, B., Abreu, C., Albuquerque, A., Allocca, M., Esteve, M., Farraye, F. A., et al. (2021) · Journal of Crohn's and Colitis · doi:10.1093/ecco-jcc/jjab052 · Cited by 480
Akiyama, S., Hamdeh, S., Micic, D., & Sakuraba, A. (2021) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2020-218946 · Cited by 383
Newer Biologic and Small-Molecule Therapies for Inflammatory Bowel Disease
Baumgart, D. C., & Le Berre, C. (2021) · New England Journal of Medicine · doi:10.1056/nejmra1907607 · Cited by 354
Metadata
- Authors
- Singh, S., Facciorusso, A., Dulai, P. S., Jairath, V., & Sandborn, W. J.
- Venue
- Clinical Gastroenterology and Hepatology
- Publisher
- Elsevier BV
- Published
- 2020-01
- Volume
- 18
- Issue
- 1
- Pages
- 69-81.e3
- ISSN
- 1542-3565 (ISSN-L)
- OpenAlex
- W2920997743
- Cited by
- 229
- References
- 2
- FWCI
- 4.13
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.